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A Ab bs st tr ra ac ct t
Central nervous system hemangioblastomas (cHAB) are rare tumours which most commonly arise in the
cerebellum. Most tumours are sporadic, but as many as one third of cHABs occur in the course of the
hereditary disorder – von Hippel-Lindau disease (VHL). In order to diagnose new VHL families in Poland we
performed sequencing of the entire VHL gene in archival material (paraffin embedded hemangioblastoma
tissues) in a large series of 203 unselected patients with cHAB. VHL gene mutations were detected in 70
(41%) of 171 tumour samples from which DNA of relatively good quality was isolated. We were able to
obtain blood samples from 19 of mutation positive cases. Eight (42%) of these harboured germline mutations
in persons from distinct undiagnosed VHL families.  
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I In nt tr ro od du uc ct ti io on n   
Central nervous system hemangioblastomas are rare
tumours which most commonly arise in the cerebellum.
Most tumours are sporadic, but as many as one third
occur in the course of the hereditary disorder – von
Hippel-Lindau disease (VHL) [1]. VHL disease is a rare
autosomal  dominant  disorder  characterized  by
a predisposition to hemangioblastomas of the central
nervous system (cHAB) and retina, renal cell carcinomas
and pheochromocytomas. The predisposition is caused
by germline mutations in the VHL tumour suppressor
gene on chromosome 3p25-26 [2]. Germline mutations
in the VHL gene are present in almost all VHL families
[3, 4]. From a clinical perspective it is very important to
distinguish  between  sporadic  and  VHL-associated
hemangioblastomas because of the risk of early onset
and multiple organ tumours in VHL families. Early
diagnosis  of  VHL  disease  allows  for  the  proper
management of not only hemangioblastomas but of
other VHL-related lesions as well. Clinical screening
according to a carefully planned surveillance schedule
results in an improved prognosis for VHL subjects [5]. 
Given the occurrence of VHL disease with a frequency
of 1:36 000 live births, it is estimated that there are as
many as 1000 VHL patients in Poland. However, to date,
the Polish VHL Registry includes only about 100 VHL
patients from 34 Polish families [4]. Thus, in order to
diagnose new VHL families in Poland, we performed
sequencing of the entire VHL gene in all available archival
material (paraffin embedded cHAB tissues) from a series
of 203 unselected patients with cHAB diagnosed in
Poland primarily in the period between 1999 and 2003. 
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s   
Tissues embedded in paraffin blocks were collected
from 203 cHAB patients operated in different Medical
Centres in Poland. Most patients were operated between
1999 and 2003, but some of them were diagnosed
prior to 1999 (Poznañ, Kraków). Paraffin blocks were
obtained from 7 neuropathology departments (Szczecin,
Poznañ,  Lublin,  Warszawa,  Katowice,  Wroc³aw,
Czêstochowa). Cases were unselected for age, clinical
presentation or family history. 
DNA  isolation  was  performed  as  described
previously  [6].  In  brief,  formalin  fixed,  paraffin
embedded tissues were sectioned into slides, then
deparaffinized in two changes of xylene. Sections were
hydrated through a series of graded alcohols. Tissues
were placed in 1.5 ml eppendorf tubes and digested
with proteinase K. After digestion, proteinase was heat
inactivated. After purification in Microcon-100 tubes
(Amicon), a solution containing DNA was diluted in
50 µl dH2O. 
The entire coding sequence of the VHL gene was
amplified  in  nested  PCR  using  6 pairs  of  primers
(available on request). In brief, 3 exons of the VHL gene
were initially amplified in 25 cycles each of 95
oC 30s,
60
oC  30s,  72
oC  30s  with  external  primers.  Then,
reamplified with internal primers in 25 PCR cycles using
the same conditions. Negative controls were used to
avoid false results. After purification, PCR products were
sequenced with the internal primers, using fluorescently
labelled dideoxy chain terminators from an ABI Prism kit
(Applied Biosystems) in an ABI 377 automated sequencer. 
R Re es su ul lt ts s
Amplification of the coding sequence of the VHL
gene was successful in 171 of 203 cHAB samples.
Automated sequencing showed VHL gene mutations in
70 (41%) of 171 tumours (Table 1). Single VHL changes
were  identified  in  67  tumours.  In  the  remaining
3 tumours two different VHL mutations were identified. 
Altogether 52 different VHL changes were identified.
Forty  eight  mutations  were  observed  in  single
hemangioblastoma cases. The following four mutations
were recurrent: 233A>G was detected in 4 cases,
239G>A present in 2 cases, 266T>A observed in
2 cases, and IVS3-1G>T identified in 17 cases. All
changes except one silent variant (Ala50Ala) resulted
in alteration of VHL protein sequence. 
Intragenic  VHL  mutations  were  non-randomly
distributed, all changes (except one silent variant) were
localized downstream codon 53. Of the 171 tumours,
36 (21%) had mutations within exon 1, 9 (5%) within
exon 2, and 5 (3%) within exon 3. In addition to these
mutations in the coding sequence we identified one of
four  splice  site  mutations  in  20  (28%)  tumours
(IVS1+1G>A, IVS2+2T>C, IVS2+2T>G in single
cases and IVS3-1G>T in 17 tumours). 
We were able to obtain blood samples from 19 of
the 70 mutation positive cases. Eight (42%) of these
harboured germline mutations and eleven (58%) had
somatic mutations present only in their tumours, but
not in peripheral blood leukocytes. 
D Di is sc cu us ss si io on n   
We identified mutations of the VHL gene in 70 (41%)
of unselected hemangioblastoma tumours. Our results
are in line with previous smaller studies showing that VHL
gene mutation is a critical event in the pathogenesis of
both familial and sporadic hemangioblastoma [7-13]. 
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Germline mutation – mutation detected in DNA from tumour and from peripheral blood leukocytes 
Somatic mutation – mutation present in tumour but not in peripheral blood leukocytes 
Uv – unverified variant (detected in tumour – blood sample not tested) 
* – mutation present in tumour tissue, but not detected in DNA isolated from blood leukocytes of four available cases – probably somatic mutation
T Ta ab bl le e   1 1. .   V VH HL L   g ge en ne e   m mu ut ta at ti io on ns s   i in n   h he em ma an ng gi io ob bl la as st to om ma a   o of f   t th he e   c ce en nt tr ra al l   n ne er rv vo ou us s   s sy ys st te em m
C Ca as se e M Mu ut ta at ti io on n C Co on ns se eq qu ue en nc ce e C Ch ha ar ra ac ct te er r
e ex xo on n1 1
1 150C>T Ala50Ala Uv
2 163G>A Glu55Lys Uv 
3 170G>C Gly57Ala Uv 
4 173G>A Arg58Gln Uv
5 174del149 In frame Somatic mutation
6 184G>A Val62Met Uv
7 193T>C Ser65Pro Germline mutation
8 194C>G Ser65Trp Uv
9 196G>A Val66Met Uv
10 206insG Frameshift Somatic mutation 
11 218A>G Gln73Arg  Uv
302T>C Leu101Pro
12 220G>A Val74Ile Uv
13 227T>A Phe76Tyr Uv
14 227T>C Phe76Ser Uv
15 232A>G Asn78Asp Somatic mutation
16 233A>G Asn78Ser Germline mutation 
17 233A>G Asn78Ser Uv
18 233A>G Asn78Ser Uv
19 233A>G Asn78Ser Uv
20 239G>A Ser80Asn Uv
21 239G>A Ser80Asn Uv 
22 240T>G Ser80Arg Uv
23 250 G>A Val84Met  Uv
24 254T>C Leu85Pro Uv
25 257 C>T Pro86Leu Uv
26 259delTAT  In frame Uv 
27 263G>A Trp88X Somatic mutation 
28 266T>A Leu89His Uv 
29 266T>A Leu89His Somatic mutation 
30 266T>C Leu89Pro Somatic mutation
194C>T Ser65Leu Germline mutation
31 266T>G Leu89Arg Uv
32 268A>T Asn90Tyr Uv
33 275A>G Asp92Gln Uv
34 334 T>C Tyr112His Somatic mutations
254del54 In frame
35 338G>A Arg113Gln Uv
36 340G>C Gly114Arg Uv
37 IVS1+1G>A Splice  Germline mutation 
e ex xo on n2 2
38 353T>C  leu118pro Uv
39 357delC Frameshift Somatic mutation
40 363delT Frameshift Uv
41 379G>A Gly127Arg Uv
42 382C>T Leu128Phe Uv
43 403T>A Leu135Ile Uv
44 437delC Frameshift Uv
45 463G>T Val155Leu Uv
46 463G>A Val155Met Germline mutation
47 IVS2+2T>C Splice Uv
48 IVS2+2T>G Splice Uv 
e ex xo on n3 3
49 474 delG Frameshift Uv
50 477-478insCA Frameshift Germline mutation
51 481C>T Arg161X Germline mutation 
52 486C>G Cys162Trp Uv 
53 499C>T Arg167Trp Germline mutation 
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Previous investigations demonstrated that the VHL
gene acts as a classic tumour suppressor gene for
sporadic and VHL-related hemangioblastomas (and
also renal cell carcinoma, pheochromocytoma and
pancreatic tumours), as inactivation of both VHL alleles
either by point mutations, loss of the entire allele or VHL
promoter methylation has been shown in these tumours
[7-13]. Although we did not investigate such somatic
events as loss of heterozygosity or promoter methylation,
in one case (no. 34) we identified two different point
mutations and demonstrated that the two somatic events
affected both VHL alleles. This is an interesting and rare
example of VHL gene inactivation by two somatic point
mutations in hemangioblastoma. Also, tumours no. 11
and  30  harboured  two  different  small  intragenic
mutations, however we did not verify whether the
mutations affected both VHL alleles. 
In the present study we detected 52 different VHL
changes. We observed different types of VHL mutations
(missense, nonsense, in-frame and frameshift deletions
and insertions, and splice site alterations), localized in
all exons of the VHL gene and downstream codon 53.
DNA alterations (including missense variants) localized
3’ of codon 53 (highly conserved region of the VHL
gene) are predicted to be true mutations [15], thus all
VHL changes (except one silent variant) reported in this
series are believed to be pathogenic. 
In the current series, most mutations were observed
in single cases. Only the IVS3-1G>T splice site mutation
was relatively common (identified in 17 cases). This
variant was present in tumour tissue, but it was not
detected in DNA isolated from blood leukocytes of four
patients. Thus, it seems that the IVS3-1G>T mutation
may  be  a somatic  event  relatively  common  in
hemangioblastoma. However, in the remaining cases,
the germline character of the IVS3-1G>T mutation
cannot be excluded. 
The incidence of VHL disease among cHAB patients
is between 5% and 30% [16, 17]. More recent reports
describe an incidence of about 40% [18, 19] and
suggest that VHL disease was underdiagnosed prior to
the introduction of modern imaging techniques and
molecular analysis of the VHL gene. In regards to the
41% prevalence of small intragenic mutations in our
group of 171 cHAB patients, and that approximately
42% of these mutations are germline (of the 19 mutation
positive hemangioblastoma tumours from whom blood
samples were available, eight (42%) harboured germline
mutations), we calculate that VHL disease caused by
intragenic mutations occurs in about 17% of unselected
hemangioblastoma patients in Poland. Given that the
sensitivity of direct sequencing is about 60% in the
diagnosis of VHL disease in the Polish population [4],
we estimate that VHL disease is present in about 25%
of unselected patients with cHAB in Poland. 
We believe that the most efficient way of diagnosis of
VHL is to provide genetic counselling to all VHL suspected
patients at the time of diagnosis of VHL-associated
lesions. In this study we showed that the analysis of
archival material from paraffin sections is relatively
efficient in searching for new VHL cases, when DNA
from peripheral blood is not available. Using this
approach, we diagnosed eight novel VHL families in
Poland  and  offered  appropriate  surveillance  and
treatment of disease to these families. 
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